Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioSante Pharmaceuticals has reacquired Elestrin from Nycomed US, which in February 2008, acquired Bradley Pharmaceuticals, BioSante's previous licensee of Elestrin.
Subscribe to our email newsletter
BioSante will immediately assume all manufacturing, distribution and marketing responsibilities for Elestrin. Elestrin is a fast-drying gel formulation of estradiol, the same estrogen produced naturally in women, and is FDA approved for the treatment of hot flashes in menopausal women.
Stephen Simes, BioSante’s president & CEO, said: “We are pleased to reacquire Elestrin since Nycomed concentrates on dermatology products and neither Bradley nor Nycomed to date were successful in marketing Elestrin.”
In addition to Elestrin which BioSante developed through the FDA approval in 2006, BioSante is actively developing LibiGel (testosterone gel) for the treatment of female sexual dysfunction in menopausal women, specifically hypoactive sexual desire disorder.